PT - JOURNAL ARTICLE AU - Ryan Ramanujam AU - Feng Zhu AU - Katharina Fink AU - Virginija Danylaitė Karrenbauer AU - Johannes Lorscheider AU - Pascal Benkert AU - Elaine Kingwell AU - Helen Tremlett AU - Jan Hillert AU - Ali Manouchehrinia AU - The BeAMS Study group TI - Accurate classification of secondary progression in multiple sclerosis AID - 10.1101/2020.07.09.20149674 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.09.20149674 4099 - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149674.short 4100 - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20149674.full AB - Transition from a relapsing-remitting to the secondary progressive phenotype is an important milestone in the clinical evolution of multiple sclerosis. In the absence of reliable imaging or biological markers of phenotype transition, assignment of current phenotype status relies on retrospective evaluation of the medical history of an individual. Here, we sought to determine if demographic and clinical information from multiple sclerosis patients can be used to accurately assign current disease phenotypes: either relapsing-remitting or secondary progressive status. Data from the most recent clinical visit of 14,387 multiple sclerosis patients were extracted from the Swedish Multiple Sclerosis Registry. Decision trees based on sex, symptom onset age, Expanded Disability Scale Status score, and age & disease duration at the most recent clinic visit, were examined to build a classifier to determine disease phenotype. Validation was conducted using an independent cohort of multiple sclerosis patients from British Columbia, Canada, and a previously published classifier to assign phenotype was also tested. Clinical records of 100 randomly selected patients were used to manually categorize phenotype by three independent neurologists. A decision tree (the classifier) containing only most recently available disability score and age obtained 89.3% (95% confidence intervals (CI): 88.8% to 89.8%) classification accuracy, defined as concordance with the latest reported status in the registry. Replication in an independent cohort from British Columbia resulted in 82.0% (95%CI: 81.0% to 83.1%) accuracy. A previously published classification algorithm with slight modifications achieved 77.8% (95%CI: 77.1% to 78.4%) accuracy when assigning disease phenotype. With complete patient history data, three neurologists obtained 84.7% accuracy on average compared with 85 for the classifier using the same data. The model is easily interpretable and could allow research studies and randomized clinical trials to estimate the probability of patients having already reached the secondary progressive stage when they have not yet been retrospectively assigned this status, and to standardize definitions of disease phenotype across different cohorts. Clinically, this model could assist neurologists by providing additional information about the probability of having secondary progressive disease. This could also benefit patients who may be introduced to new therapies targeting progressive multiple sclerosis.Competing Interest StatementRR has nothing to disclose. AM is supported by the Margaretha af Ugglas Foundation KF received an unrestricted research grant from Biogen, NeuroFonden and Neurofobundet. KF has received travel compensation for lectures for Novartis, Biogen, TEVA, Almirall and Merck. VK received financial support from Stockholm County Council and Biogen's Multiple Sclerosis Registries Research Fellowship Program. VK has also received an unrestricted grant from Biogen and a project grant from Novartis. JH received honoraria for serving on advisory boards for Biogen and Genzyme and speaker's fees from Biogen, Novartis, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Sanofi-Genzyme and Novartis. His multiple sclerosis research is funded by the Swedish Research Council and the Swedish Brain Foundation. HT is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. Current research support received from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last five years, has received research support from the UK MS Trust; travel expenses to present at CME conferences from the Consortium of MS Centres (2018), the National MS Society (2016, 2018), ECTRIMS/ ACTRIMS (2015, 2016, 2017, 2018, 2019, 2020), American Academy of Neurology (2015, 2016, 2019). Speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by HT's research group. EK is supported through research grants from the Canadian Institutes of Health Research and the Multiple Sclerosis Society of Canada. In addition, during the last five years, she has received travel expenses to give presentations, or attend CME conferences, from ACTRIMS, ECTRIMS, and the MS Society of Canada. PB and FZ have nothing to disclose. JL received research support from Innosuisse Swiss Innovation Agency, research grants from Biogen and Novartis and honoraria for serving on advisory boards from Roche and Teva. Funding StatementThis study was funded by the Swedish Strategic Research Foundation, the Swedish Brain foundation and by the Swedish Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for the study was granted by the Stockholm Regional Ethical Committee and the University of British Columbia's Clinical Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Swedish data related to the current article are available from Jan Hillert, Karolinska Institutet. To be able to share data from the Swedish multiple sclerosis registry, a data transfer agreement along with appropriate ethical permissions need to be obtained between Karolinska Institutet and the institution requesting data access. This is in accordance with the data protection legislation in Europe (General Data Protection Regulation [GDPR]). Persons interested in obtaining access to the data should contact Ali Manouchehrinia (ali.manouchehrinia{at}ki.se).